Skip to main content

Table 1 Baseline characteristics and 5-year LRR rates of 4841 pT1–2 N0 breast cancer patients after mastectomy

From: Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy

Variables n (%) 5-year LRR (%) p
Treatment era
 1999–2007 1915 (39.6) 5.5 < 0.001
 2008–2014 2926 (60.4) 2.8
Age (years)
 Median 51.1 ± 10.5   
  ≤ 40 723 (14.9) 7.5 < 0.001
  > 40 4118 (85.1) 3.3
Tumor quadrant
 Inner 1255 (25.9) 5.3 < 0.001
 Non-inner 3486 (72.0) 3.0
 Unknown 100 (2.1) 18.9
pT stage
 T2 1954 (40.4) 5.3 0.003
 T1 2887 (59.6) 3.0
Molecular subtype
 Luminal 3150 (65.0) 2.8 < 0.001
 Her2 overexpression 501 (10.3) 5.0
 Triple-negative 1076 (22.2) 6.5
 Unknown 114 (2.4) 5.3
LVI
 Yes 184 (3.8) 8.1 0.011
 No 4631 (95.7) 4.0
 Unknown 26 (0.5) 11.6
Tumor grade
 I and II 2803 (57.9) 3.3 0.012
 III 1137 (23.5) 5.1
 Unknown 901 (18.6) 4.6
Histology
 IDC 4399 (90.9) 4.0 0.356
 ILC 141 (2.9) 1.9
 IMPC 26 (0.5) 0.0
 MBC 4 (0.1) 0.0
 Medullary carcinoma 56 (1.2) 6.0
 Other 215 (4.4) 2.4
Adjuvant chemotherapy
 Yes 3236 (66.8) 2.1 < 0.001
 No 1605 (33.2) 4.8
Endocrine therapy
 Yes 3113 (64.3) 2.8 < 0.001
 No 1682 (34.7) 6.1
 Unknown 46 (1.0) 0.0
 Median time (months) 44.7 ± 21.6   
Anti-Her2 target therapy
 Yes 233 (4.8) 3.4 0.372
 No 4580 (94.6) 4.0
 Unknown 28 (0.6) 0.0
  1. ER Estrogen receptor, Her2 Human epidermal growth factor receptor 2, IDC Invasive ductal carcinoma, ILC Invasive lobular carcinoma, IMPC Invasive micropapillary carcinoma, LRR Locoregional recurrence, LVI Lymphovascular invasion, MBC Metaplastic breast carcinoma, PR Progesterone receptor
\